glucokinase


Also found in: Medical, Acronyms, Encyclopedia, Wikipedia.

glucokinase

(ˌɡluːkəʊˈkaɪneɪz)
n
(Biochemistry) biochem an enzyme that regulates carbohydrate metabolism

glu•co•ki•nase

(ˌglu koʊˈkaɪ neɪs, -neɪz)

n.
an enzyme that catalyzes the phosphorylation of glucose.
[1950–55]
References in periodicals archive ?
1168-P : TTP399, a Liver Selective Glucokinase Activator (GKA) that Preserves the Physiological Regulation of Glucokinase (GK) by GK Regulatory Protein (GKRP)
Molecular cloning of hepatic glucose-6-phosphate catalytic subunit from gilthead sea bream (Sparus aurata): Response of its mRNA levels and glucokinase expression to refeeding and diet composition.
A drug targeting glucokinase could prevent obesity, the scientists believe.
Glucokinase activators have the potential to differentiate from other anti-diabetic agents by exerting two potentially beneficial actions: promoting insulin secretion and decreasing glucose production by the liver.
Biotin increases pancreatic glucokinase expression via soluble guanylate cyclase/protein kinase G and autocrine feedback action of insulin.
88) Fructose which is present in significant proportions in most honeys has been shown to enhance glucokinase and glycogen synthase activities and inhibit phosphorylase activity in the liver.
Glucokinase is an enzyme that regulates the uptake of glucose from the blood.
Growing evidence on the effects of mutations in the glucokinase (GCK) gene, which appear to account for approximately 5% of gestational diabetes cases in white mothers, may similarly drive screening efforts in the future, he said.
In addition, a SNP in the gene glucokinase (hexokinase 4) regulator (GCKR), which encodes glucokinase regulatory protein, was found to have a highly significant association with triglyceride concentrations (67).
9) Thus patients with glucokinase mutations (MODY 2) have an altered glucose set point for beta cell insulin secretion, which leads to modest elevations of fasting and post-prandial blood glucose levels from birth that progress little with advancing age and carry no risk of complications; most individuals with MODY 2 can be taken off all glycaemic therapy.
The agreement between TransTech Pharma and Forest Laboratories involving glucokinase activator program, for the treatment of diabetes, was the largest deal in Q2 2010, valued at USD 1.